PERSEVERE Passes Early Accuracy Test
Research By: Hector Wong, MD
Post Date: November 13, 2019 | Publish Date: Nov. 13, 2019
Researchers at Cincinnati Children’s have successfully tested the new PERSEVERE rapid blood assay, which uses just five biomarkers to accurately predict whether critically ill children receiving intensive care are at low, medium or high risk for death from sepsis.
Detailed findings were published online Nov. 13, 2019, in Science Translational Medicine.
Beyond data from mouse models, the research team led by Hector Wong, MD, Director of Critical Care Medicine at Cincinnati Children’s, obtained permission from patient families and the Institutional Review Boards of participating institutions, to test blood samples from 461 children receiving intensive care.
The predict model proved as accurate for the children as it had for the mice. However, since PERSEVERE is not yet approved for clinical use, it was not used to inform or influence patient care decisions. It was tested only for accuracy and potential future use.
|Prospective clinical testing and experimental validation of the Pediatric Sepsis Biomarker Risk Model
|Science Translational Medicine
|Nov. 13, 2019